Hand-Foot Skin Reaction: An Illustrative Case and Review of the Recent Literature

Summary: Regorafenib is a multikinase inhibitor that is often used in the management of hepatocellular carcinoma, gastrointestinal stromal tumors (GIST), and colorectal cancer. However, several adverse events have been documented with regorafenib use, including hand-foot skin reaction (HFSR). While this is a well documented side effect, no standard guidelines currently exist for preventing and managing regorafenib-associated HFSR, or for HFSR and hand-foot syndrome related to other chemotherapy agents. We present a unique case of regorafenib-induced HFSR in an adolescent patient with osteosarcoma. This case highlights the importance of early recognition and treatment of HFSR in an effort to prevent interruptions in anticancer therapy.